Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This Opinion article discusses the contributions of bioengineering, especially biomaterials engineering, to our understanding of cancer biology and to the development of emerging therapeutic strategies such as cancer immunotherapy.
Somatic genetic mosaicism has been demonstrated in many tissues, leading to interactions between functionally diverse cell populations that could contribute to homeostasis ('clonal health') or influence disease states. These authors argue that embryonic somatic mosaicism can contribute to adult cancers.
Genome-based cancer therapeutic matching is limited by incomplete biological understanding of the relationship between phenotype and cancer genotype. This Opinion article proposes that this limitation can be addressed by functional testing of live patient tumour cells exposed to potential therapies.
This Opinion article outlines a set of research priorities, based on discussions held at the 2015 Helene Harris Memorial Trust Ovarian Cancer Action meeting, that the authors believe will reduce incidence and improve outcomes for women with high-grade serous ovarian cancer.
What is the best approach to avoid resistance to therapies that target intracellular signalling pathways? In this Opinion article, Gonda and Ramsay argue that increased effort should be made to target transcriptional regulators directly.
Most cancer genomics studies have focused on identifying the most important somatic mutations ('major drivers') that promote tumour growth. However, many cancer-associated mutations might instead have relatively weak tumour-promoting effects. This Opinion article highlights the existence of these mutations (termed 'mini drivers') and the functional effects that they might have.
Aberrations in gene expression due to an altered epigenotype that is widely distributed in normal tissues are referred to as constitutional epimutations. This Opinion article discusses the potential contribution of constitutional epimutations to the 'missing' causality and heritability of cancer.
Activation of the peripheral nervous system can promote metastasis of primary tumours. This Opinion article discusses the molecular mechanisms through which physiological stress can have an effect on cancer, and how pharmacological antagonism of β-adrenergic signalling might represent a therapeutic opportunity to target cancer progression.
This Opinion describes the early interactions between immune cells and pre-neoplastic cells observed in translucent zebrafish andDrosophila melanogastermodels, and speculates on their potential implications in human cancer.
In this Opinion article, Brocket al. analyse how intrinsic variability in gene expression in proliferating cells, as well as microenvironmental signals, can drive cells to transform into a neoplastic state or revert to a normalized state.
Inborn errors of metabolism are inherited monogenic disorders caused by mutations in genes encoding metabolic enzymes that can result in malignancy. This Opinion article discusses how studying these rare diseases might provide insight into how specific metabolic changes contribute to cancer initiation, development, diagnosis and treatment.
Heterogeneous expression of the epidermal growth factor receptor (EGFR) in glioblastoma poses an important challenge for the effective use of EGFR-targeted therapies. In this Opinion article, Furnariet al. highlight the possible mechanisms underlying EGFR heterogeneity, and the importance in understanding these mechanisms to improve treatment outcome in glioblastoma.
This Opinion article advocates therapeutically targeting the niches that harbour dormant disseminated tumour cells in order to make them susceptible to cytotoxic agents. Similar strategies have sensitized leukaemic cells and latent HIV to therapy, and such an approach might delay or even prevent metastasis.
There is evidence that African-American women with triple-negative breast cancer (TNBC) have worse clinical outcomes than women of European descent with TNBC. However, it is unclear whether survival differences persist after adjusting for health disparities. Understanding the relative contributions of biology and disparities is crucial for improving the poor survival of African-American women with TNBC.